Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Krka was established in Slovenia in 1954, and has grown to become one of the largest generic drug manufacturers in Central and Eastern Europe. With the acquisition of Lek by Novartis in late 2002, Krka is now the only major Slovenian-owned pharmaceutical company.

Krka's largest therapeutic category is cardiovascular drugs, followed by anti-infectives, alimentary tract and metabolism products, CNS drugs and respiratory drugs. The company has marketed its own enalapril and omeprazole products for 15 years. Recent launches of Tenox, Krka's amlodipine maleate product, and Coryol, its carvedilol product in Western Europe have boosted the company's sales.

Exports accounted for 87.1% of Krka's sales in 2006. The company's largest region in terms of sales is Eastern Europe, accounting for around 30% of overall sales.